Center for Scientific Review; Notice of Closed Meeting, 78052-78053 [2023-25072]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES 78052 Federal Register / Vol. 88, No. 218 / Tuesday, November 14, 2023 / Notices 73. Kathleen Staub, Dresher, Pennsylvania, Court of Federal Claims No: 23–1611V 74. Shireesha Eedunuru on behalf of R. R. K., Sugarland, Texas, Court of Federal Claims No: 23–1613V 75. Anna Hoffman, Summit, Wisconsin, Court of Federal Claims No: 23–1614V 76. Sarah Leah Ganzweig, New York, New York, Court of Federal Claims No: 23– 1615V 77. Adi Eminente, Los Angeles, California, Court of Federal Claims No: 23–1616V 78. Nancy Hodges, Fresno, California, Court of Federal Claims No: 23–1617V 79. Debora Strader, Escondido, California, Court of Federal Claims No: 23–1619V 80. Dairinn Finn, Olean, New York, Court of Federal Claims No: 23–1620V 81. Gabrielle Rawnsley, Charleston, New Hampshire, Court of Federal Claims No: 23–1621V 82. James A. Bristol, Jr., McKinney, Texas, Court of Federal Claims No: 23–1622V 83. Jamie Whitehouse, Helena, Montana, Court of Federal Claims No: 23–1623V 84. Christal Hanson, Boston, Massachusetts, Court of Federal Claims No: 23–1624V 85. Karen Bergin, New London, Connecticut, Court of Federal Claims No: 23–1625V 86. Amanda Page, Louisburg, North Carolina, Court of Federal Claims No: 23–1626V 87. Nazeer Lotfi-Fard, Avon, Ohio, Court of Federal Claims No: 23–1627V 88. Travis Rian, Wellesley, Massachusetts, Court of Federal Claims No: 23–1628V 89. Eugene Hieger, Lexington, Kentucky, Court of Federal Claims No: 23–1630V 90. Wendy Wright, Lewiston, Idaho, Court of Federal Claims No: 23–1631V 91. Bruce A. Scott, Fort Recovery, Ohio, Court of Federal Claims No: 23–1632V 92. Kathleen Hicks, Mechanicsville, Virginia, Court of Federal Claims No: 23–1634V 93. Rebecca Fellows, Lebanon, New Hampshire, Court of Federal Claims No: 23–1636V 94. Natalie Gaines, Columbia, Maryland, Court of Federal Claims No: 23–1637V 95. Michael Todaro, Dresher, Pennsylvania, Court of Federal Claims No: 23–1638V 96. Nicole Schaefer, Charleston, South Carolina, Court of Federal Claims No: 23–1641V 97. Annie Murphy, Ann Arbor, Michigan, Court of Federal Claims No: 23–1642V 98. Kristena Rivera on behalf of L. R., Dresher, Pennsylvania, Court of Federal Claims No: 23–1644V 99. Kerri Stone on behalf of E. L., Lexington, South Carolina, Court of Federal Claims No: 23–1645V 100. Toni Rankin, Beverly Hills, California, Court of Federal Claims No: 23–1646V 101. Gregory Whitehouse, Boston, Massachusetts, Court of Federal Claims No: 23–1647V 102. Melvin J. Martin on behalf of Billy J. Martin, Deceased, Greensboro, North Carolina, Court of Federal Claims No: 23–1649V 103. James Brady, Boston, Massachusetts, Court of Federal Claims No: 23–1650V 104. Julio Castillo, South Jordan, Utah, Court of Federal Claims No: 23–1651V 105. Jesus Villahermosa, Gig Harbor, Washington, Court of Federal Claims No: VerDate Sep<11>2014 16:48 Nov 13, 2023 Jkt 262001 23–1652V 106. Theresa V. Barrows, Cambridge, Vermont, Court of Federal Claims No: 23–1653V 107. Grisel Escalera, Providence, Rhode Island, Court of Federal Claims No: 23– 1654V 108. Margaret Carter, Dresher, Pennsylvania, Court of Federal Claims No: 23–1656V 109. Stacy Brown-Satterwhite, Greensboro, North Carolina, Court of Federal Claims No: 23–1658V 110. Jerilynn Vokurka, Phoenix, Arizona, Court of Federal Claims No: 23–1659V 111. Debra Legleiter, Harrison, Arkansas, Court of Federal Claims No: 23–1660V 112. Brenda Smull, Chandler, Arizona, Court of Federal Claims No: 23–1662V 113. Lois Blankenship on behalf of Carter Blankenship, Deceased, Crown Point, Indiana, Court of Federal Claims No: 23– 1663V 114. Curtis Lovejoy, Altamont, Illinois, Court of Federal Claims No: 23–1664V 115. Evelyn Fisher, Bensalem, Pennsylvania, Court of Federal Claims No: 23–1665V 116. Mary Palmisano, New Brunswick, New Jersey, Court of Federal Claims No: 23– 1666V 117. Alina Dennis, Chula Vista, California, Court of Federal Claims No: 23–1670V 118. Julie Brown, Libertyville, Illinois, Court of Federal Claims No: 23–1671V 119. Raymond Motyka, East Orange, New Jersey, Court of Federal Claims No: 23– 1672V 120. Carl Bildner, Columbia, Missouri, Court of Federal Claims No: 23–1673V 121. Deborah Bagdazian, San Diego, California, Court of Federal Claims No: 23–1674V 122. Misty Fuller, Glenwood Springs, Colorado, Court of Federal Claims No: 23–1677V 123. Jeanne Carpenter, Glen Burnie, Maryland, Court of Federal Claims No: 23–1678V 124. John J. Reding, Jr., Seattle, Washington, Court of Federal Claims No: 23–1679V 125. Gina Goldmann, Islandia, New York, Court of Federal Claims No: 23–1681V 126. Bruce W, Blais, Jr., Providence, Rhode Island, Court of Federal Claims No: 23– 1682V 127. Von-Ikenna Marie Tresna-Taylor, Fulton, Missouri, Court of Federal Claims No: 23–1687V 128. Kenneth Berard, Vancouver, Washington, Court of Federal Claims No: 23–1690V 129. Bradley McKinnon, Little Rock, Arkansas, Court of Federal Claims No: 23–1691V 130. Melinda Boards, Bowling Green, Kentucky, Court of Federal Claims No: 23–1692V 131. Dora D. Loiacono, West Caldwell, New Jersey, Court of Federal Claims No: 23– 1693V DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2023–25043 Filed 11–13–23; 8:45 am] Pursuant to section 1009 of the Federal Advisory Committee Act, as BILLING CODE 4165–15–P PO 00000 Frm 00105 Fmt 4703 Sfmt 4703 National Institutes of Health National Center for Advancing Translational Sciences; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; Preclinical Proof of Concept Studies for Rare Diseases (R21) Review Meeting. Date: January 24–25, 2024. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, MSC 4874 Bethesda, MD 20892, (301) 402–1744, carol.kim@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: November 8, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–25070 Filed 11–13–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting E:\FR\FM\14NON1.SGM 14NON1 78053 Federal Register / Vol. 88, No. 218 / Tuesday, November 14, 2023 / Notices amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–22– 233: Time-Sensitive Opportunities for Health Research. Date: December 8, 2023. Time: 11:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Wenjuan Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480–8667, wangw22@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: November 8, 2023. Patricia B. Hansberger, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2023–25072 Filed 11–13–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; Cancer Therapy Evaluation Program (CTEP) Branch and Support Contracts Forms and Surveys (NCI) AGENCY: National Institutes of Health, HHS. ACTION: Notice. Branch and Support Contracts Forms and Surveys (NCI), 0925–0753, Expiration Date 03/31/2026, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: This is a request for OMB to approve the revised information collection, Cancer Therapy Evaluation Program (CTEP) Support Contracts Forms and Survey. It includes modifications to OMB-approved forms for the CTSU and CIRB and the addition of new forms for the CTSU, CIRB, and CTEP. The National Cancer Institute (NCI) CTEP and the Division of Cancer Prevention (DCP) fund an extensive national program of cancer research, sponsoring clinical trials in cancer prevention, symptom management, and treatment for qualified clinical investigators. As part of this effort, CTEP implements programs to register clinical site investigators and clinical site staff and to oversee the conduct of research at the clinical sites. CTEP and DCP also oversee two support programs, the NCI Central Institutional Review Board (CIRB) and the Cancer Trial Support Unit (CTSU). The combined systems and processes for initiating and managing clinical trials are termed the Clinical Oncology Research Enterprise (CORE) and represent an integrated set of information systems and processes that support investigator registration, trial oversight, patient enrollment, and clinical data collection. The information collected is required to ensure compliance with applicable federal regulations governing the conduct of human subjects’ research (45 CFR 46 and 21 CRF 50), and when CTEP acts as the Investigational New Drug (IND) holder (Food and Drug Administration (FDA) regulations pertaining to the sponsor of clinical trials and the selection of qualified investigators under 21 CRF 312.53). Survey collections assess satisfaction and provide feedback to guide improvements with processes and technology. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 162,831 hours. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Michael Montello, Cancer Therapy Evaluation Program—DCTD, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland 20850 or call non-toll-free number (240) 276–6080 or email your request, including your address to: montellom@ mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Proposed Collection Title: Cancer Therapy Evaluation Program (CTEP) SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Number of responses per respondent Average burden per response (in hours) Total annual burden hours Form name Type of respondent CTSU IRB/Regulatory Approval Transmittal Form (Attachment A01). CTSU IRB Certification Form (Attachment A02) .. Health Care Practitioner 2444 12 2/60 978 Health Care Practitioner 2444 12 10/60 4888 VerDate Sep<11>2014 16:48 Nov 13, 2023 Jkt 262001 PO 00000 Frm 00106 Fmt 4703 Sfmt 4703 E:\FR\FM\14NON1.SGM 14NON1

Agencies

[Federal Register Volume 88, Number 218 (Tuesday, November 14, 2023)]
[Notices]
[Pages 78052-78053]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25072]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as

[[Page 78053]]

amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR-22-233: Time-Sensitive Opportunities for Health Research.
    Date: December 8, 2023.
    Time: 11:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Wenjuan Wang, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institute of Health, 6701 
Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480-8667, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: November 8, 2023.
Patricia B. Hansberger,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-25072 Filed 11-13-23; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.